Drug Cost Management Report - Eli Lilly’s new drug for attention deficit hyperactivity disorder , Strattera, may have trouble getting reimbursement from HMO formularies - ADHD - Eli Lilly…
Monday, December 29th, 2008* Eli Lilly’s new drug for attention deficit hyperactivity disorder (ADHD), Strattera, may have trouble getting reimbursement from HMO formularies, according to a study by Decision Resources. The drug is a latecomer to this therapeutic category, which includes some generics, and relationships between HMOs and manufacturers are fairly well-cemented.
Relat…
